Pazopanib activity confirmed in EWSR1-NFATC2 bone sarcoma

A new case report was published in Oncoscience (Volume 10) on September 20, 2023, entitled, “Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma.”

Risk Adjusted Net Present Value: What is the current valuation of Celltrion’s Aflibercept Biosimilar.

Share this article The revenue for Aflibercept Biosimilar. is expected to reach an annual total of $233 mn by 2039 globally based off GlobalData’s Revenue

November 19, 2023

California moves ahead of the FDA in banning common candy additives

Halloween candy could be in for a California makeover.

October 20, 2023

In-hospital delirium linked to long-term cognitive impairment in COVID-19 patients over 60

The association of in-hospital delirium with functional disability and cognitive impairment.

July 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.